



CURIS LIFESCIENCES PRIVATE LIMITED

CIN: U24230GJ2016PTC086559

BALANCE SHEET AS ON 31 MARCH, 2022

(Rs. In Lakhs)

Particulars	Note No.	As at 31 March, 2022	As at 31 March, 2021
EQUITY AND LIABILITIES			
Shareholders' funds			
(a) Share Capital	3	50.00	50.00
(b) Reserves and Surplus	4	-113.02	-191.19
(c) Money Received against share warrants			
		-63.02	-141.19
Share application money pending allotments			
Non-Current liabilities			
(a) Long-term Borrowings	5	1240.53	1554.87
(b) Deferred Tax Liabilities (net)		-	-
(c) Other Long-term Liabilities		-	-
		1240.53	1554.87
Current liabilities			
(a) Short-term Borrowings			
(b) Trade Payables	6	521.82	503.72
(i) dues of micro enterprises and small enterprises	7	943.55	577.00
(ii) dues other than micro enterprises and small enterprises			
(c) Other Current Liabilities	8	131.55	110.20
(d) Short-term Provisions	9	12.50	-
		1609.41	1190.93
TOTAL		2786.92	2604.60
ASSETS			
Non-Current Assets			
(a) (i) Property, Plant & Equipments			
(ii) Tangible Assets	10	1233.37	1269.92
(iii) Capital Work In Progress		-	-
(iv) Intangible Assets under Development		-	-
		1233.37	1269.92
(b) Non-Current Investments	11	.50	.50
(c) Long-term Loans and Advances			
(d) Deferred Tax Assets (net)	12	45.32	65.91
(e) Other Non Current Assets	13	18.19	18.19
		64.02	84.60
Current Assets			
(a) Inventories	14	537.53	293.64
(b) Trade Receivables	15	625.32	630.32
(c) Cash and Cash Equivalents	16	11.09	11.63
(d) Short-term Loans and Advances	17	315.59	314.50
(e) Other Current Assets			
		1489.54	1250.09
TOTAL		2786.92	2604.60

See accompanying notes forming part of the financial statements

In terms of our report attached

For, B. T. VORA & Co.

Chartered Accountants

FRN: 123652W


C. A. SHETH
PARTNER

M.No. : 180506


UDIN: 22180506AXTNGS8165



For & On Behalf of Board of Directors


Directors

DIN: 07371003


Directors

DIN: 07371033

Place : Ahmedabad

Date : 09-09-2022

Place : Ahmedabad

Date : 09-09-2022

**CURIS LIFESCIENCES PRIVATE LIMITED**

CIN: U24230GJ2016PTC086559

STATEMENT OF PROFIT AND LOSS FOR THE YEAR END 31 MARCH, 2022

(Rs. In Lakhs)

Particulars	Note No.	For the year ended 31 March, 2022	For the year ended 31 March, 2021
Revenue From Operations			
Revenue from operations (gross)	18	2374.10	2126.00
Other Income	19	1.28	31.01
Total Income		2375.38	2157.01
Expenses			
(a) Cost of materials consumed	20 a	1449.36	1408.20
(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	20 b	-59.75	-52.00
(c) Purchase of Stock in Trade		4.15	3.83
(d) Employee benefits expense	21	355.16	293.42
(e) Finance costs	22	161.63	155.39
(f) Depreciation and amortisation expense	10	75.49	69.77
(g) Other expenses	23	276.28	215.37
Total expenses		2262.32	2093.98
Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)		113.06	63.03
Exceptional items {Prior Year Expenses/(Income)/net}	24	1.81	6.83
Profit / (Loss) before extraordinary items and tax (5 ± 6)		111.25	56.19
Extraordinary items			
Profit / (Loss) before tax (7 ± 8)		111.25	56.19
Tax expense:			
(a) Income tax for current year		12.50	-
(b) Income tax for earlier year		-	-
(c) Net current tax expense (a+b)		12.50	-
(d) Deferred tax (Income)/Expenses		20.58	5.34
		33.08	5.34
Profit / (Loss) from continuing operations (9 + 10)		78.17	50.85
Earnings per share of Rs.10/- each:			
(a) Basic	25	15.63	10.17
(b) Diluted	25	15.63	10.17

See accompanying notes forming part of the financial statements

In terms of our report attached

For, **B. T. VORA & Co.**

Chartered Accountants


FRN: 123652W

C. A. SHETH

PARTNER

M.No. : 180506

UDIN: 22180506AXTNGS8165



For and on behalf of the Board of Directors

Directors
DIN: 07371003

Directors
DIN: 07371033

Place : Ahmedabad

Date : 09-09-2022

Place : Ahmedabad

Date : 09-09-2022

Curis Lifesciences Private Limited

F.Y.: 2021-22

Statement of Significant Accounting Policies and Notes Forming Part of the Accounts for the Year ended 31st March, 2022

Note: 1) Significant Accounting Policies

1. Basis for preparation of Financial Statements

The financial statement has been prepared under the historical cost convention, in accordance with Accounting Standards issued by the Institute of Chartered Accountants of India and the Provisions of the Companies Act, 2013, as adopted consistently by the Company. All income and expenditure having a material bearing on the financial statements are recognized on accrual basis.

2. Use of estimates

The preparation of financial statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on date of the financial statement and the reported amount of revenues and expenses during the reporting period.

Difference between the actual result and estimate are recognized in the period in which the result are known / materialized.

3. Sales and Purchase:

Sales:

Sales are recorded when supply of goods takes place in accordance with the terms of sale and is exclusive of GST and net of claim for shortage. Rate difference and Goods return.

Purchase:

Purchases are accounted as per purchase invoice and are net of credit GST receivable.

4. Inventories:


- a) Finished Goods are valued at cost
- b) Stock in process is valued at cost plus allocable expenses.
- c) Raw Material & Packing Material are valued at cost inclusive of freight. Cost is arrived at on FIFO Basis and is net of CENVAT credit

5. Property, Plant & Equipments:

The fixed assets are stated at the cost of acquisition including inward freight, duties & taxes and other incidental expenses less refundable duties, taxes and depreciation.

6. Depreciation:

Depreciation on fixed asset is provided on Straight Line Method in accordance with Section 123(2) of the Companies Act, 2013 as per useful life and in the manner prescribed in Schedule II of the said Act.



7. GST:

GST payable and GST and Cenvat receivable are accounted on the basis of return submitted. Additional liabilities if any on assessment / audit objections shall be provided / paid as and when the assessment is completed.

8. Employee Benefit:

The contribution to defined Contribution Scheme of Provident Fund & ESIC for Employees is charged to the Profit & Loss Account as incurred.

As per views of management Leave encashment provision is not required on account of companies own leave rule, hence Leave encashment to employees are not provided and shall be accounted as and when paid, if any.

9. Investments:

Investments are valued at cost of acquisition.

10. Prior Period Items:

Items of income and expenditure which relating to prior accounting period, if any are accounted in the Statement of Profit and Loss account under the head prior year adjustments.

11. Taxation:


The current charge for income taxes is calculated in accordance with the relevant tax regulations applicable to the company. Deferred tax assets and liabilities are recognized for further tax consequences attributable to the timing difference that result between the profit offered for income tax and the profit as per the financial statements. Deferred tax assets and liabilities are measured as per the tax rates laws that have been enacted or substantively enacted by the Balance Sheet date.

12. Contingent Liabilities and Assets:

Contingent liability is recognized and provided for when the company has present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligations and of which a reliable estimate can be made. Contingent liability is disclosed in notes to the accounts in case if obligation is disputed and the possibility of an outflow of resources is remote. Contingent assets are not recognized until the realization of income is virtually certain as per views of the management.

13. Impairment:

The carrying amount of assets are reviewed at each Balance Sheet date, if there is, any Indication of impairment based on internal/external factor. An impairment loss is recognized whenever the carrying amount of an asset exceed it recoverable amount. The recoverable amount is grater of asset's net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value.



14. Foreign Currency Transaction:

- a) Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction or that approximates the actual rate at the date of transaction.
- b) Monetary items denominated in foreign currencies at the year-end are restated at the Year-end rates.
- c) Any income or expenses on account of exchange difference either on settlement or on Translation is recognized in the Statement of profit and Loss.

15. Borrowing Cost:

Borrowing costs that are attributable to the acquisition or construction of qualifying are capitalized as part of the cost of such asset. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to statements of Profit and Loss.

16. Government Grants / Subsidy

Government grants, if any, are accounted when there is reasonable assurance that the enterprise will comply with the conditions attached to them and it is reasonably certain that the ultimate collection will be made. Capital Subsidy in nature of Government Grants related to specific fixed assets is accounted for where collection is reasonably certain and the same is shown as a deduction from the gross value of the asset concerned in arriving at its book value and accordingly the depreciation is provided on the reduced book value. Subsidy on Interest and Subsidy received for Electricity are charged to profit & loss account treating it as Revenue Receipt.


17. Events Occurring after Balance Date:

Events occurring after the date of Balance Sheet are considered up to date of adoption of the accounts where it was material.

For, B. T. Vora & Co.
Chartered Accountants
FRN: 123652W


C. A. SHETH
Partner

Mem. No.:180506
UDIN: 22180506AXTNGS8165
Place: Ahmedabad
Date: 09-09-2022



For, CURIS LIFESCIENCES PVT LTD



Director
(DIN: 07371003)



Director
(DIN: 07371033)

Note: 2) Notes to Accounts

(1) The company has not reconciled the balances with various parties appearing under grouping of sundry debtors, loans & advances and sundry creditors. Hence impact of such reconciliation, if any, is not ascertained.

(2) The figures have been rounded up to the nearest rupee.

(3) Current Assets

The Board of directors of the company is of the opinion that the current assets, loans & advances of Capital Goods as on 31st March, 2022 have a value of realization in the ordinary course of business or at least equal to the amount at which they are stated in the balance Sheet and the provision for all known liabilities have been made.

(4) Retirement Benefit:

Provident Fund is defined contribution scheme and the contributions are charged to profit & loss account of the year when the contribution to the respective funds is due. The company has not ascertained requirement of AS-15 post employment benefit as per requirement of AS - 15 and has no define policy thereof.

As per views of management Leave encashment provision is not required on account of companies own leave rule, hence Leave encashment to employees are not provided and shall be accounted as and when paid, if any.

(5) Letter of confirmation of balances to parties and Bank have not been issued and hence balances of creditors, debtors, loans & advances (Credit/ Debit) are subject to adjustments, if any, on reconciliation/settlement of respective accounts.

(6) In accordance with accounting standard AS-22 accounting for taxes on income issued by the ICAI the company has accounted deferred taxes during the year.

(7) The Company has not received any intimation from Supplier regarding their status under the Micro, Small and Medium Enterprise Development Act 2006 and hence disclosure relating to Amount unpaid as on year and together with interest paid, payable as required under that Act have not been given.



(8) Related Party Transaction (AS-18)


KEY MANAGEMENT PERSONS	NATURE OF TRANSACTION	2021-22	2020-21
JAIMIK M PATEL	Remuneration	900000	675000
DHARMESH PATEL	Remuneration	750000	475000
PIYUSH ANTALA	Remuneration	800000	875000
SIDDHANT J. PAWASIA	Remuneration	900000	675000
<u>RELATED PARTIES:</u>			
JAIMIK M PATEL	Interest	741755	495000
DHARMESH PATEL	Interest	1661669	1606636
PIYUSH ANTALA	Interest	905761	798418
SIDDHANT J. PAWASIA	Interest	1822448	2246104
DEEPALIBEN S. PAWASIA	Salary	300000	477600
BIOCARE FORMULATION	Purchase	125504	214067
BIOCARE FORMULATION	Sales	4130	51713
BIOCARE FORMULATION	Interest	0	0
SYZER LIFESCIENCES	Sales	8740	848000
SYZER LIFESCIENCES	Purchase	2360	0
SYZER LIFESCIENCES	Capital Goods	177700	0
MACLINE PHARMACEUTICALS	Sales	0	139297
MANSUKHBHAI GOKALDAS PATEL	Interest	550099	0
HEMAL PRAVINKUMAR BABARIA	Interest	965812	0

(9) In accordance with accounting standard AS-22 accounting for taxes on income issued by the ICAI the company has accounted deferred taxes during the year.

(10) The Company has not received any intimation from Supplier regarding their status under the Micro, Small and Medium Enterprise Development Act 2006 and hence disclosure relating to Amount unpaid as on year and together with interest paid, payable as required under that Act have not been given.

(11) Other Additional Regulatory Requirements

i. The Title deeds of the immovable properties are held in the name of the Company except given below



Relevant line item in the Balance sheet	Description of item of property	Gross carrying value	Title deeds held in the name of	Whether title deed holder is a promoter, director or relative# of promoter*/director or employee of promoter/director	Property held since which date	Reason for not being held in the name of the company**
-	-	-	-	-	-	-

- ii. As per the Company's accounting policy, Property, Plant and Equipment (including Right of Use Assets) and intangible assets are carried at historical cost (less accumulated depreciation & impairment, if any), hence the revaluation related disclosures required as per Additional Regulatory Information of Schedule III (revised) to the Companies Act, is not applicable.
- iii. No proceedings have been initiated or pending against the Company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder.
- iv. The Company has sanctioned facilities from banks on the basis of security of current assets. The periodic returns filed by the Company with such banks are in agreement with the books of accounts of the Company as appears from the documents.
- v. The Company has adhered to debt repayment and interest service obligations on time. Willful defaulter related disclosures required as per Additional Regulatory Information of Schedule III (revised) to the Companies Act, is not applicable.
- vi. There are no transactions with the companies whose name are struck off under Section 248 of The Companies Act, 2013 or Section 560 of the Companies Act, 1956 during the year ended 31st March, 2022.
- vii. There are no charges or satisfaction yet to be registered with ROC beyond the statutory period.
- viii. There are no instances where the company has not complied with the layers prescribed under clause (87) of the section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.
- ix. There are no Scheme of Arrangements approved by the Competent Authority in terms of Sections 230 to 237 of the Companies Act, 2013, in accordance with the Scheme' and 'in accordance with accounting standards' and any deviation in this regard.
- x. The Company has not invested or traded in Crypto Currency or Virtual Currency during the financial year/period.
- xi. The Company has not advanced or loan or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities




- (Intermediaries) with the understanding (whether recorded in writing or otherwise) that Intermediary shall:
- a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or in behalf of the Company (Ultimate Beneficiaries) or
 - b) Provide any guarantee, security or the like on behalf of Ultimate Beneficiaries.
- xii. The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Intermediaries) with understanding that the Intermediary shall:
- a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or in behalf of the Company (Ultimate Beneficiaries) or
 - b) Provide any guarantee, security or the like on behalf of Ultimate Beneficiaries
- xiii. The company does not have any transaction not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under Income Tax Act, 1961 (such as, search or survey or any other relevant provision of the Income Tax Act, 1961), unless there is immunity for disclosure under any scheme and shall also state whether the previously unrecorded income and related assets have been properly recorded in the books of accounts during the year.
- xiv. In the opinion of the management all current loans and advances would be realizable at least by the amount equal to the amount at which they are stated in the balance sheet. Provisions have been made for all known and accrued liabilities.
- xv. The previous period figures have been regrouped/reclassified/rounded off wherever necessary to conform to the current presentation.
- xvi. The accounting ratios as suggested in amendment to Schedule III of Companies Act, 2013 are attached separately.

For, B. T. Vora & Co.
Chartered Accountants
FRN: 123652W



C. A. SHETH
Partner

Mem. No.:180506
UDIN: 22180506AXTNGS8165
Place: Ahmedabad
Date: 09-09-2022



For, CURIS LIFESCIENCES PVT LTD



Director
(DIN: 07371003)



Director
(DIN: 07371033)

CURIS LIFESCIENCES PRIVATE LIMITED
NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

Note 3 : Share capital

(Rs. In Lakhs)

Particulars	As at 31 March, 2022		As at 31 March, 2021	
	Number of shares	Amt. (In Rs.)	Number of shares	Amt. (In Rs.)
(a) Authorised				
Equity Shares of Rs.10/- each	500,000	5,000,000	500,000	5,000,000
TOTAL	500,000	5,000,000	500,000	5,000,000
(b) Issued, Subscribed and Paid up				
Equity shares of Rs. 10/- each	500,000	5,000,000	500,000	5,000,000
TOTAL	500,000	5,000,000	500,000	5,000,000

Details of shares held by each shareholder holding more than 5% shares:

Name of Shareholders	No. of Shares	%	Value/Share	Total Value
Dharmesh Dashrathbhai Patel	100,000	20.00%	10	10.00
Piyush Gordhanbhai Antala	115,000	23.00%	10	11.50
Jaimik Mansukhbhai Patel	75,000	15.00%	10	7.50
Siddhant Jayantibhai Pawasia	140,000	28.00%	10	14.00
Jayantibhai Dayaljibhai Pawasia	50,000	10.00%	10	5.00
TOTAL	480,000	10.00%		48.00

SHARES HELD BY PROMOTORS

Current Reporting Period

Sr No.	Promotor's Name	No of shares	% of total shares	% Change during the year
1	Dharmesh Dashrathbhai Patel	100000	20.00%	
2	Piyush Gordhanbhai Antala	115000	23.00%	
3	Jaimik Mansukhbhai Patel	75000	15.00%	
4	Siddhant Jayantibhai Pawasia	140000	28.00%	
5	Jayantibhai Dayaljibhai Pawasia	50000	10.00%	
6	Mansukhbhai Patel	15000	3.00%	
7	Hemal Babaria	5000	1.00%	

Previous reporting Period

Sr No.	Promotor's Name	No of shares	% of total shares	% Change during the year
1	Dharmesh Dashrathbhai Patel	100000	20.83%	
2	Piyush Gordhanbhai Antala	115000	23.96%	
3	Jaimik Mansukhbhai Patel	75000	15.63%	
4	Siddhant Jayantibhai Pawasia	140000	29.17%	
5	Jayantibhai Dayaljibhai Pawasia	50000	10.42%	
6	Mansukhbhai Patel	3000	0.63%	
7	Hemal Babaria	1000	0.21%	

STATEMENTS OF CHANGES IN EQUITY

Current Reporting Period

Balance at the beginning of the current reporting period	Changes in Equity Share Capital due to prior period error	Related Balance at the beginning of the current reporting period	Changes in Equity Share Capital during the current year	Balance at the end of the current reporting period
500,000				500,000

Previous reporting Period

Balance at the beginning of the previous reporting period	Changes in Equity Share Capital due to prior period error	Related Balance at the beginning of the previous reporting period	Changes in Equity Share Capital during the previous year	Balance at the end of the previous reporting period
500,000				500,000

CURIS LIFESCIENCES PRIVATE LIMITED

NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

Note 4 : Reserves and Surplus

(Rs. In Lakhs)

Particulars	As at 31 March, 2022	As at 31 March, 2021
(a) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	-191.19	-242.04
Add: Profit / (Loss) for the year	78.17	50.85
Closing balance	-113.02	-191.19

Note 5 : Long-term Borrowings

Particulars	As at 31 March, 2022	As at 31 March, 2021
(i) Secured, considered good		
From Banks :		
AMCO Machine Loan Account - 18	45.27	135.25
AMCO Machine Loan Account - 30	121.19	136.30
AMCO Shed Loan Account - 03 (Secured against hypothication of Plant & Machineries, Factory Land & Building & Personal Gurantee of the Directors)	167.40	228.82
HDFC Bank - Bus Loan A/c (Secured against hypothication of vehicle)	3.19	7.86
	337.05	508.22
(ii) Unsecured, considered good		
From Directors		
Dharmesh D Patel	273.40	303.63
Piyush Gordhanbhai Antala	233.34	233.01
Jaimik Mansukhbhai Patel	128.66	131.45
Siddhant Jayantibhai Pawasia	112.29	194.86
	747.70	862.95
From Shareholders		
Mansukhbhai Gokaldas Patel	51.74	84.50
Hemal Pravinkumar Babaria	39.04	39.20
Jayantibhai Dayaljibhai Pawasia	60.00	60.00
	150.78	183.70
From Inter Corporates		
SOTAC PHARMACEUTICALS PVT LTD - LOAN	5.00	
	5.00	.00
Total	1240.53	1554.87

CURIS LIFESCIENCES PRIVATE LIMITED

NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

Note 6 : Short-Term Borrowings

(Rs. In Lakhs)

Particulars	As at 31 March, 2022	As at 31 March, 2021
Secured Borrowing		
From Bank		
AMCO CC Loan Account - 16 (Secured against hypothecation of Stock and Trade Receivables & Personal Gurantee of the Directors)	359.95	358.25
Current Maturities of Long-term Debt		
From Bank		
AMCO Machine Loan Account - 18	82.16	73.27
AMCO Machine Loan Account - 30	20.03	18.27
AMCO Shed Loan Account - 03	54.61	48.70
Kotak Mahindra Prime - Car Loan	.00	.35
HDFC Bank - Bus Loan A/c	5.08	4.66
Trade Deposits		
Unsecured, considered good	.00	.23
TOTAL	521.82	503.72

Note 8 : Other Current Liabilities

Particulars	As at 31 March, 2022	As at 31 March, 2021
	Amt. (In Rs.)	Amt. (In Rs.)
(a) Statutory Remittances		
TCS on Goods Payable	.38	.73
TDS payable	1.44	1.80
TDS payable (Contract)	1.49	1.15
TDS payable (on Interest)	6.65	5.25
TDS ON COMMISSION PAYABLE	.05	.13
TDS ON PROFESSIONAL FEE PAYABLE	.28	.22
TDS ON RENT PAYABLE	.51	.47
TOTAL	10.80	9.75
(b) Other Payables		
Advance From Customers	35.53	33.97
Unpaid Expenses	85.21	66.48
TOTAL	120.75	100.45
TOTAL (A+B+C)	131.55	110.20

Note 9 : Short Term Provision

Particulars	As at 31 March, 2022	As at 31 March, 2021
Income Tax Provisions (MAT)	12.50	-
TOTAL	12.50	-

CURIS LIFESCIENCES PRIVATE LIMITED
NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

Note 10 : Property, Plant & Equipments

Tangible assets	Gross block				Accumulated depreciation and impairment				Net block		
	As at 31 March, 2021	Additions during the year	Disposals / Transfer to 95% Block during the year	As at 31 March, 2022	As at 31 March, 2021	Depreciation Transfer From 95% Block	Provided For the year	Eliminated on Transfer of Assets	As at 31 March, 2022	As at 31 March, 2021	
Land	73.68			73.68	.00				-	73.68	73.68
Air Conditioner	13.73	.00		13.73	9.02		2.61		11.63	2.10	4.71
Factory Building	427.92	.00		427.92	46.71		13.55		60.26	367.66	381.21
Computers	12.93	.45		13.38	12.02		.35		12.37	1.00	.91
Furniture And Fixtures	36.67	.07		36.74	22.89		6.98		29.87	6.87	13.78
Plant & Machinery	815.31	39.40	1.04	853.67	98.37		39.68	.06	137.98	715.69	716.94
Lab Equipment	30.07	-		30.07	9.73		2.86		12.58	17.49	20.34
Office Equipments	7.07	-		7.07	4.51		1.34		5.85	1.21	2.56
Electric Fittings & Equipment	53.20	-		53.20	16.96		5.05		22.02	31.18	36.23
Telephone & EPBX	.98	-		.98	.64		.19		.83	.15	.34
Vehicle	24.31	-		24.31	5.10		2.89		7.99	16.33	19.21
Total	1495.87	39.92	1.04	1534.75	225.95		75.49	.06	301.38	1233.37	1269.92
Previous Year	1276.03	229.51	9.67	1495.87	157.44	.00	69.77	1.26	225.95	1269.92	1118.59

Note 11 : Non-Current Investments

Particulars	As at 31 March, 2022		As at 31 March, 2021	
	Quoted	Unquoted	Quoted	Unquoted
Investments				
Amco Bank Shares	-	.50	-	.50
Total Investments		.50		.50

CURIS LIFESCIENCES PRIVATE LIMITED
NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

Note 7 TRADE PAYABLES

Figures As At 31 March 2022

(Rs. In lakhs)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	-	-	-	-	-
Others	-	-	-	-	-
For Raw Material	541.37	-	-	-	541.37
For Packing Material	286.66	-	-	-	286.66
For Capital Goods	41.64	-	-	-	41.64
For Expenses	73.88	-	-	-	73.88
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	-	-	-	-	-
Total	943.55	.00	.00	.00	943.55

Figures As At 31 March 2021

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	-	-	-	-	-
Others	-	-	-	-	-
For RM Goods	252.90	-	-	-	252.90
For PM Goods	198.03	-	-	-	198.03
For Capital Goods	52.53	-	-	-	52.53
For Expense	73.54	-	-	-	73.54
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	-	-	-	-	-
Total	577.00				577.00

Note 14 TRADE RECEIVABLES

Figures As At 31 March 2022

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	605.55	12.07	7.70	-	-	625.32
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-

Figures As At 31 March 2021

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	587.42	29.16	-	-	-	616.58
Undisputed Trade Receivables- Considered Doubtful	-	-	13.74	-	-	13.74
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-

CURIS LIFESCIENCES PRIVATE LIMITED
NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

(Rs. In Lakhs)

Note 12 : Deferred Tax Liabilities / (Assets) (net)

Particulars	As at 31 March, 2022	As at 31 March, 2021
Deferred Tax Liabilities		
Timing diff. between book and tax depreciation	-95.81	-84.78
Deferred Tax Assets		
On Carried forward Losses & Unabsorbed Depreciation	141.14	150.69
Total	45.32	65.91

Note 13 : Other Non Current Assets

Particulars	As at 31 March, 2022	As at 31 March, 2021
(a) Security Deposits		
Unsecured, considered good		
UGVCL Deposit	16.79	16.79
RENT DEPOSIT	1.20	1.20
VAT Deposit	.10	.10
CST Deposit	.10	.10
Total	18.19	18.19

Note 14 : Inventories

Particulars	As at 31 March, 2022	As at 31 March, 2021
Raw Materials	260.36	121.51
Packing Material	139.46	94.16
Stock in Process	137.71	77.97
Total	537.53	293.64

Note 16 : Cash & Cash Equivalents

Particulars	As at 31 March, 2022	As at 31 March, 2021
(a) Cash on hand	11.07	9.92
(b) Balances with banks		
Amco Bank	.02	1.71
Total	11.09	11.63

Note 17 : Short-term loans and advances

Particulars	As at 31 March, 2022	As at 31 March, 2021
(a) Prepaid expenses - Unsecured, considered good		
PREPAID INSURANCE	1.43	1.13
PREPAID LICENSE FEES	.36	.91
PREPAID EXPENSES	-	.22
PREPAID LICENCE FEE FOR SIERRA LEONE	5.50	-
PREPAID POLLUTION CONTROL BOARD FEE	.15	.24
(A)	7.44	2.49
(b) Balances with government authorities	303.32	306.82
(c) Others		
Advance for Capital Goods	1.68	1.68
KNK Wealth Consultant	.00	.25
Staff Loan	2.53	2.55
Interest Receivable from UGVCL	.63	.70
(C)	4.84	5.18
Total (A+B+C)	315.59	314.50

CURIS LIFESCIENCES PRIVATE LIMITED

NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

PARTICULARS	For the Year Ended 2021-22	For the Year Ended 2020-21
NOTES : 18 : Revenue From Operation		
(a) Sales of products		
Manufacturing Goods	2165.81	2052.95
Add: Freight on Sales	1.09	3.70
Net Sales (a)	2166.89	2056.64
(b) Other Operating Income		
Product Permission Charges Collected	1.08	2.09
Cylinder Charges (net)	2.61	2.08
Job Work Income	202.87	63.55
Plate Charges Collected	.65	.78
Consulting Charges		.85
TOTAL (b)	207.21	69.36
Revenue from Operation (Gross) (a+b)	2374.10	2126.00
Total----->>>>>>	2374.10	2126.00
NOTES : 19		
2) Other Income		
a) Interest Income	.78	30.76
b) Other Non Operating Income	.51	.25
Total----->>>>>>	1.28	31.01
NOTES : 20.A		
a) Cost Of Raw Material Consumed		
Opening Stock of Raw Material	121.51	155.99
Add: Raw Material Purchased	1136.99	965.81
	1258.50	1121.81
Less: Closing Stock of Raw Material	260.36	121.51
Total Raw Material Consumed	998.14	1000.30
(b) Cost of Packing Material Consumed		
Opening Stock of Packing Material	94.16	64.10
Add: Packing Material Purchased	496.52	437.97
	590.68	502.07
Less: Closing Stock of Packing Material	139.46	94.16
Total Packing Material Consumed	451.22	407.91
Note: Composition of Purchases		
Rawmaterial and Packing Material Purchased During The Year		
Indigenous Raw Material	1136.99	965.81
Indigenous Packing Material	496.52	437.97
	1633.51	1403.78
Total Material Purchase	1633.51	1403.78

CURIS LIFESCIENCES PRIVATE LIMITED

NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

PARTICULARS	For the Year Ended 2021-22	For the Year Ended 2020-21
NOTES : 20.B		
b) Change of inventories of finished goods, work in progress and stock in trade		
Inventories at the end of year		
Finished Goods		
Stock in process	137.71	77.97
	137.71	77.97
Inventories at the beginning of year		
Finished Goods		
Stock in process	77.97	25.97
	77.97	25.97
Net (Increase) / Decrease	-59.75	-52.00
NOTES : 21		
Employee Benefits Expenses		
Salary, Wages & Bonus	306.78	255.83
M.D./Directors Remmu. & Allowance	33.50	27.00
Contribution to Provident & Other Funds	10.76	8.28
Staff Welfare Expenses	4.12	2.32
Total----->>>>>>	355.16	293.42
NOTES : 22		
Finance Cost		
a) Interest Expenses On:		
 i) Borrowing		
	161.63	155.35
 ii) Others		
Interest on Income Tax	.00	.04
Total----->>>>>>	161.63	155.39
NOTES : 23: Other Expenses		
Manufacturing Expenses		
Spare Purchase	5.74	8.84
Cylinder Charges	2.69	3.40
Plate Charges	.83	1.38
Product Permission Charges	2.54	.74
Sterio Stamping Exp	1.80	1.54
Cotton Rags Purchase	1.12	.83
Consulting Charges	.20	.00
Frieght on Purchase	2.10	1.46
Insurance on Purchase	.09	.11
Job Work Exp	.37	.99
Laboratory Exp	.00	.36
Labour charges	.93	1.23
LDO Purchase	42.21	27.46
Oil Purchase	.52	.28
Electricity	75.60	65.31
Lab Testing Charges	6.21	11.34
Other Manufacturing Expense	.21	1.49

CURIS LIFESCIENCES PRIVATE LIMITED

NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

NOTES : 23 : Other Expenses (Continued...)		
Other Expenses		
Bus Fuel Exp	2.70	2.52
Bad Debts Written Off	15.64	.00
Commission Charges	4.70	4.54
Cartage	9.40	6.51
Conveyance	2.94	2.21
Computer & Software Exps	1.17	.81
Donation & Contribution	.00	.05
Foreign Exchange Fluctuation loss	.00	.04
Factory & Site Exp	4.10	3.68
Hospitality Exps	1.13	2.75
Insurance Exp	1.85	1.14
Legal & Professional *	3.72	3.26
Other Expenses	15.67	7.51
Packing & Fowarding Exps	.25	.80
Printing & Stationary	7.41	7.38
Loan Processing Charges	1.97	4.63
Loading & Unloading Charges	1.09	.42
Local Frieght RCM	.16	1.16
Loss on sale of Machinery	.00	.61
Municipal Tax	.00	.77
Repairs & Maintanance (Machinery)	22.75	16.58
Repairs & Maintanance (Building)	3.96	.98
Rent Exp	5.12	4.66
Registration & Tender fees	10.06	3.11
Security Exp	6.52	4.67
Travelling Exps	.96	.26
Vehicle Repairing	1.03	.52
Water Charges	7.37	5.59
Payments To Auditors :		
As Auditors - Statutory Audit	.70	.60
For Taxation Matter	.50	.45
For Other Professional Services	.25	.40
	1.45	1.45
Total----->>>>>>	276.28	215.37

CURIS LIFESCIENCES PRIVATE LIMITED
NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

PARTICULARS	For the Year Ended 2021-22	For the Year Ended 2020-21
	Amt. (In Rs.)	Amt. (In Rs.)
Note : 24 : Prior Period Adjustments (net)		
Prior Period Expenses	2.10	11.83
Prior Period Income	.29	5.00
TOTAL	1.81	6.83
Note : 25 Earning Per Share (EPS)		
Net profit after tax has been used as numerator and no. of shares has been used as denominator for calculation		
Face Value per Share (In Rs.)	10	10
Net Profit after Tax	78.17	50.85
Weighted average no. of shares	500,000	500,000
Basic and diluted Earning Per Share	15.634	10.171

Calculation of weighted average no of share

Share outstanding at the beginning of the year	500000
The new share issued equivalent to outstanding for the whole year	0
Total Share outstanding for the whole year	500000